Renaissance Technologies LLC lowered its holdings in VYNE Therapeutics Inc. (NASDAQ:VYNE – Free Report) by 21.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 63,111 shares of the company’s stock after selling 17,465 shares during the period. Renaissance Technologies LLC owned approximately 0.43% of VYNE Therapeutics worth $124,000 at the end of the most recent quarter.
Separately, Virtu Financial LLC purchased a new position in VYNE Therapeutics in the 1st quarter valued at approximately $50,000. Hedge funds and other institutional investors own 83.78% of the company’s stock.
Analyst Ratings Changes
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $5.75 price target on shares of VYNE Therapeutics in a report on Thursday, September 12th.
VYNE Therapeutics Stock Up 3.8 %
Shares of VYNE opened at $1.91 on Monday. VYNE Therapeutics Inc. has a twelve month low of $1.57 and a twelve month high of $4.48. The stock has a market cap of $28.17 million, a PE ratio of -0.74 and a beta of 1.40. The business’s 50-day moving average price is $1.84 and its 200-day moving average price is $2.18.
VYNE Therapeutics (NASDAQ:VYNE – Get Free Report) last posted its earnings results on Wednesday, August 14th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.03). The firm had revenue of $0.20 million during the quarter, compared to analysts’ expectations of $0.11 million. VYNE Therapeutics had a negative return on equity of 43.11% and a negative net margin of 5,849.18%. Analysts expect that VYNE Therapeutics Inc. will post -0.86 earnings per share for the current fiscal year.
About VYNE Therapeutics
VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.
Recommended Stories
- Five stocks we like better than VYNE Therapeutics
- CD Calculator: Certificate of Deposit Calculator
- Why Fastenal Stock Could Hit New Highs After Strong Q3 Results
- The Role Economic Reports Play in a Successful Investment Strategy
- Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
- 3 Ways To Invest In Coffee, Other Than Drinking It
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
Want to see what other hedge funds are holding VYNE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VYNE Therapeutics Inc. (NASDAQ:VYNE – Free Report).
Receive News & Ratings for VYNE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VYNE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.